Abion Inc. engages in the development of chemical and biological drugs, and vaccines in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a drug candidate for lung and stomach cancer; ABN501, a biomarker for ovarian cancer; and ABN201, a fusion protein to target cancer cells. It also develops ABN101, an interferon-beta based biological drug for the treatment of autoimmune diseases in the central nervous system. In addition, the company is developing medical countermeasure vaccines, such as ABN701, a vaccine that protects against infection from staphylococcal enterotoxin B; and ABN601, a drug for the protection of immune system from acute radiation syndrome. Abion Inc. was founded in 2007 and is based in Seoul, South Korea.